Today, a Major Shareholder at Integra Lifesciences (NASDAQ: IART), Richard Caruso, sold shares of IART for $2.95M.
Following Richard Caruso’s last IART Sell transaction on March 12, 2018, the stock climbed by 7.9%.
See today’s analyst top recommended stocks >>
Based on Integra Lifesciences’ latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $366 million and quarterly net profit of $11.38 million. In comparison, last year the company earned revenue of $279 million and had a net profit of $3.16 million. IART’s market cap is $5.4B and the company has a P/E ratio of 72.35. Currently, Integra Lifesciences has an average volume of 341.7K.
Based on 6 analyst ratings, the analyst consensus is Hold with an average price target of $64.40, reflecting a 1.5% upside.
The insider sentiment on Integra Lifesciences has been negative according to 76 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Richard Caruso’s trades have generated a 16.4% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical and Orthopedics and Tissue Technologies segments.
